One of neuroscience's most stubborn engineering problems — how to deliver therapeutic molecules into the brain without invasive surgery or systemic exposure — may be closer to a practical solution than previously assumed. A non-invasive nasal route capable of targeting mRNA directly to diseased brain tissue would transform treatment prospects for traumatic brain injury, neuroinflammatory conditions, and potentially neurodegenerative diseases affecting tens of millions of adults.
The research team developed a class of peptide-based ionizable lipid nanoparticles optimized specifically for intranasal brain delivery, exploiting the anatomical continuity between the nasal cavity and the central nervous system via olfactory and trigeminal nerve pathways. Critically, systematic screening revealed that positively charged mRNA-LNP formulations produced markedly superior brain transfection compared to neutral or negatively charged variants — a surface-charge dependency that had not been clearly established for this delivery route. The optimized construct, designated INBT LNP, demonstrated brain-selective mRNA expression with minimal off-target activity in peripheral organs. In a repetitive mild traumatic brain injury mouse model, intranasal co-delivery of mRNAs encoding brain-derived neurotrophic factor (BDNF) and interleukin-10 (IL-10) produced measurable reductions in neuroinflammation and neuronal death, alongside improved cognitive performance.
This work sits at an important intersection: lipid nanoparticle technology is already clinically validated through COVID-19 mRNA vaccines, and the nose-to-brain pathway has been explored for small molecules and peptides for years. What is genuinely novel here is the systematic optimization of LNP surface charge for intranasal CNS mRNA delivery combined with dual-payload therapeutic efficacy. Key limitations must be acknowledged — all efficacy data are from mouse models, interspecies differences in olfactory anatomy mean human translation requires substantial additional work, and long-term safety profiles for repeated intranasal LNP administration remain unestablished. Nonetheless, the platform's noninvasive character and the ability to encode virtually any therapeutic protein via mRNA gives this approach meaningful versatility. This is an incremental-but-directionally-significant advance warranting close attention as human feasibility studies are designed.